Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Nathan Pennell, MD, PhD, and Laura J. Tafe, MD, provide medical oncology and pathology perspectives, respectively, when answering questions from a clinician audience on topics including:
Nathan Pennell, MD, PhD
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Laura J. Tafe, MD
Associate Professor of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
The Geisel School of Medicine at Dartmouth
Hanover, New Hampshire
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer
Downloadable resource on the role of RET and NTRK aberrations in lung and thyroid cancer, including guidance on testing and review of the clinical data on RET and NTRK inhibitor therapy for these diseases, from Clinical Care Options (CCO)
Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)
Download this slideset for an overview of key data on immunotherapy in early-stage resectable and stage III unresectable NSCLC, from Clinical Care Options (CCO)